(Q39639008)

13 September 2017

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities (English)

1 reference

13 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

5

Johann De Bono

1 reference

13 September 2017

Heather Payne

1

1 reference

13 September 2017

Amit Bahl

series ordinal

2

1 reference

13 September 2017

Malcolm Mason

series ordinal

3

1 reference

13 September 2017

Janis Troup

series ordinal

4

1 reference

13 September 2017

19 March 2012

1 reference

13 September 2017

1 reference

13 September 2017

110

1 reference

13 September 2017

5

1 reference

13 September 2017

658-667

1 reference

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

13 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Castration-resistant prostate cancer: current and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10886.X

10.1111/J.1464-410X.2011.10886.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference